Clinical trials for Uveal melanoma
51 recruiting or active trials synced from ClinicalTrials.gov.
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data- RECRUITINGN/ANCT07364474Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the LiverMassachusetts General Hospital · PI: Eric Wehrenberg-Klee, MD
- RECRUITINGPhase 3NCT07015190Neoadjuvant Darovasertib in Primary Uveal MelanomaIDEAYA Biosciences
- RECRUITINGPhase 2NCT07276386Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal MelanomaH. Lee Moffitt Cancer Center and Research Institute · PI: Jonathan Zager, MD, FACS
- RECRUITINGPHASE1, PHASE2NCT06961357Clinical Trial of CD40L-augmented TIL for Patients With Advanced MelanomaH. Lee Moffitt Cancer Center and Research Institute · PI: Lilit Karapetyan, MD
- RECRUITINGPhase 1NCT07203391Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell HomeostasisSt Vincent's Hospital, Sydney · PI: Anthony Joshua, MBBS PhD FRACP
- RECRUITINGPhase 1NCT07076550A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic MelanomaAlpha-9 Oncology USA Inc.
- RECRUITINGNCT07421739Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) SubjectsAura Biosciences · PI: Study Director
- RECRUITINGPHASE1, PHASE2NCT06626516Tebentafusp-tebn With LDT in Metastatic UMThomas Jefferson University · PI: Rino Seedor, MD
- RECRUITINGPhase 2NCT06414590Neoadjuvant Tebentafusp for Uveal MelanomaThomas Jefferson University
- RECRUITINGPhase 2NCT06070012Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal MelanomaDiwakar Davar · PI: Diwakar Davar, MD, PhD
- RECRUITINGPhase 2NCT07057596Neoadjuvant Tebentafusp in Patients With Metastatic Uveal MelanomaGrupo Español Multidisciplinar de Melanoma · PI: Josep Maria Piulats, M.D., Ph.D.
- RECRUITINGPHASE1, PHASE2NCT07063875Adding IL-2 to Tebentafusp to Eradicate Cancer ProgressionSt Vincent's Hospital, Sydney · PI: Anthony Joshua, FRACP
- RECRUITINGPhase 2NCT06932757Adjuvant Quisinostat in High-Risk Uveal MelanomaUniversity of Miami · PI: Jose Lutzky, MD
- RECRUITINGPHASE1, PHASE2NCT06940739A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive LifileucelIovance Biotherapeutics, Inc. · PI: Iovance Biotherapeutics Study Team
- ACTIVE NOT RECRUITINGPhase 2NCT06717126A Randomised Phase II Study of Roginolisib in Patients With Advanced/Metastatic Uveal MelanomaiOnctura · PI: Michael Lahn, MD
- RECRUITINGPhase 2NCT06627244Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal MelanomaUniversity of Miami · PI: Lynn Feun, MD
- RECRUITINGN/ANCT06970236Resistance Exercise in Patients With Ocular MelanomaUniversity of Valencia
- RECRUITINGPHASE2, PHASE3NCT06581406A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal MelanomaReplimune Inc. · PI: Rahul Marpadga, MD MPH
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT06784648Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic MelanomaBioInvent International AB
- RECRUITINGPhase 3NCT06246149Adjuvant Tebentafusp in High Risk Ocular MelanomaEuropean Organisation for Research and Treatment of Cancer - EORTC · PI: Paul Nathan
- RECRUITINGPhase 2NCT06121180Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal MelanomaH. Lee Moffitt Cancer Center and Research Institute · PI: Ahmad Tarhini, MD, PHD
- RECRUITINGN/ANCT06550674Identification of New Candidate Genes for Hereditary Predisposition to Uveal MelanomaCentre Jean Perrin · PI: Mathis LEPAGE, Dr
- ACTIVE NOT RECRUITINGNCT06432660Eye Plaque Brachytherapy for Ocular MelanomaDuke University · PI: Dianda Ayala-Peacock, MD
- RECRUITINGPhase 3NCT06519266PHP in Combination With IPI1/NIVO3 Compared to IPI3/NIVO1 Only in Patients With Uveal Melanoma Liver MetastasesVastra Gotaland Region · PI: Roger Olofsson Bagge, Professor
- RECRUITINGPhase 3NCT06007690A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal MelanomaAura Biosciences · PI: Medical Monitor
- ACTIVE NOT RECRUITINGN/ANCT06075589Psychoeducation for Uveal MelanomaJonsson Comprehensive Cancer Center · PI: Anette Stanton, PhD
- ACTIVE NOT RECRUITINGPHASE2, PHASE3NCT05987332IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal MelanomaIDEAYA Biosciences · PI: Hetal Patel, MD, MSHS, CHCQM
- ACTIVE NOT RECRUITINGPhase 2NCT05907954(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular MelanomaIDEAYA Biosciences · PI: Jasgit Sachdev, MD
- RECRUITINGNCT05733728Retrospective Register for Uveal MelanomaMedical University of Vienna
- RECRUITINGPhase 2NCT05524935Olaparib in Combination With Pembrolizumab for Advanced Uveal MelanomaH. Lee Moffitt Cancer Center and Research Institute · PI: Nikhil I Khushalani, MD
- RECRUITINGPhase 3NCT05502900Adjuvant Melatonin for Uveal MelanomaGustav Stalhammar · PI: Gustav Stålhammar, MD PhD
- ACTIVE NOT RECRUITINGPhase 2NCT05308901Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal MelanomaProvidence Health & Services · PI: Matthew Taylor, MD
- ACTIVE NOT RECRUITINGPhase 2NCT05315258Tebentafusp in Molecular Relapsed Disease (MRD) MelanomaUniversity of Oxford · PI: Mark Middleton
- RECRUITINGPhase 1NCT05496686Targeted Alpha Particle Radiotherapy for Metastatic Uveal MelanomaModulation Therapeutics, Inc. · PI: Mark L McLaughlin
- ACTIVE NOT RECRUITINGPhase 2NCT05282901Efficacy and Safety of Pembrolizumab in Combination With Lenvatinib in Metastatic Uveal MElanoma Patients (PLUME)Institut Curie · PI: Manuel Rodrigues, MD
- ACTIVE NOT RECRUITINGPhase 2NCT05187884Neoadjuvant/Adjuvant Trial of Darovasertib in Ocular MelanomaSt Vincent's Hospital, Sydney · PI: Anthony Joshua, FRACP, MBBS, PhD
- ACTIVE NOT RECRUITINGPhase 2NCT05170334Binimetinib Plus Belinostat for Subjects With Metastatic Uveal MelanomaH. Lee Moffitt Cancer Center and Research Institute · PI: Ahmad Tarhini, MD, PhD
- ACTIVE NOT RECRUITINGPhase 2NCT04728633Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver MetastasesThomas Jefferson University · PI: Carin Gonsalves, MD
- RECRUITINGPhase 2NCT05077280A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal MelanomaCalifornia Pacific Medical Center Research Institute · PI: David R Minor, MD
- ACTIVE NOT RECRUITINGNCT04588662A Prospective Natural History Study in Uveal MelanomaColumbia University · PI: Mariam El-Ashmawy, MD, PhD
- ENROLLING BY INVITATIONPHASE1, PHASE2NCT05893654Melphalan Chemoreduction for Ocular MelanomaHospital das Clínicas de Ribeirão Preto · PI: Rodrigo Jorge, MD, PhD
- RECRUITINGPhase 1NCT04855435Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid TumoursMonTa Biosciences ApS · PI: Kristoffer S Rohrberg, MD PhD
- RECRUITINGPHASE1, PHASE2NCT04729543MAGE-C2 TCR T Cell Trial to Treat Melanoma and Head and Neck CancerErasmus Medical Center
- RECRUITINGN/ANCT04424719Follow-up of Patients With Uveal Melanoma Adapted to the Risk of Relapse (SALOME)Institut Curie · PI: Sophie Piperno-Neumann, MD
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04283890PHP and Immunotherapy in Metastasized UMLeiden University Medical Center · PI: Ellen W. Kapiteijn, MD, PhD
- RECRUITINGNCT03941379A Registry of Subjects With Primary Indeterminate Lesions or Choroidal MelanomaAura Biosciences · PI: Medical Monitor
- RECRUITINGNCT05377957Prospective Registration Of Patient Data and Quality of Life in Eye Melanoma PatientsLeiden University Medical Center · PI: Nanda Horeweg, Md PhD
- ACTIVE NOT RECRUITINGPhase 2NCT02068586Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal MelanomaSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University · PI: Takami Sato, MD
- ACTIVE NOT RECRUITINGPhase 2NCT01979523Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal MelanomaNational Cancer Institute (NCI) · PI: Alexander N Shoushtari
- ACTIVE NOT RECRUITINGPhase 2NCT01587352Vorinostat in Treating Patients With Metastatic Melanoma of the EyeNational Cancer Institute (NCI) · PI: Alexander N Shoushtari
- RECRUITINGNCT01438658Assessing the Clinical Effectiveness of Serum Biomarkers in the Diagnosis of Metastatic Uveal MelanomaHadassah Medical Organization · PI: Shahar Frenkel, MD, PhD